LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2,…

• UD
  U.S. Department of Defense
• UD
  U.S. Department of Energy
• EL
  Eli Lilly and Company
• UO
  University of Texas Medical Branch
• VR
  Vaccine Research Center
• NI
  National Institutes of Health

  Award: UC7AI094660
• DA
  Defense Advanced Research Projects Agency
• OO
  Office of Science
• H2
  Horizon 2020 Framework Programme
• H2
  Horizon 2020

  Award: 653316
• NI
  National Institute of Allergy and Infectious Diseases
• DS
  Defense Sciences Office, DARPA

  Award: D18AC00002
• AN
  Argonne National Laboratory